Hematologic Malignancy
Adult Acute Myeloid Leukemia
CI-CAN-00004346Explore in graph →
Hematologic64 active trials
- NCIt
- C9154
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004346Explore in graph →
Clinical trials
374 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (72)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03146871 | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent | terminated | Phase 2 | 7 | University of Southern CaliforniaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06449482 | Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Institute of Hematology & Blood Diseases Hospital, China |
| 1 |
| May 30, 2025 |
| clinicaltrials |
| NCT03537599 | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 4 | Sumithira VasuOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer | terminated | Phase 1 / Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT04079738 | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | terminated | Phase 1 / Phase 2 | 8 | H Scott BoswellOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT04425655 | Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. | terminated | Phase 2 | 2 | University of California, San DiegoOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT01640301 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 47 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 14, 2022 | clinicaltrials |
| NCT01876953 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03951961 | Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation | terminated | Phase 2 | 1 | University of JenaOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT02038153 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 3 | Albert Einstein College of MedicineOTHER | 1 | May 14, 2020 | clinicaltrials |
| NCT02337478 | Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 2 | 5 | Wake Forest University Health SciencesOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02634827 | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation | terminated | Phase 2 | 1 | Mayo ClinicOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02030405 | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 2 | 4 | Steven E. CoutreOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT01907815 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia | terminated | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2018 | clinicaltrials |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT01342887 | Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00673153 | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | terminated | Phase 2 | 31 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00863434 | Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT01465386 | Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission | terminated | Phase 2 | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01607645 | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS | terminated | Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00052598 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02029417 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2016 | clinicaltrials |
| NCT01521936 | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy | terminated | Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00089388 | Cilengitide in Treating Patients With Acute Myeloid Leukemia | terminated | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00096148 | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jun 8, 2026source: clinicaltrials